Zeki: /* Breastfeeding */

2024-07-05T06:21:03Z

Breastfeeding

← Older revision		Revision as of 02:21, 5 July 2024
Line 79:		Line 79:
	Not recommended		Not recommended

	==Breastfeeding==		'''Breastfeeding

	Not recommended		Not recommended

Zeki at 06:20, 5 July 2024

2024-07-05T06:20:33Z

← Older revision		Revision as of 02:20, 5 July 2024
Line 6:		Line 6:

	'''Canagliflozin (INVOKANA)'''（中文：[[卡格列淨]]）		'''Canagliflozin (INVOKANA)'''（中文：[[卡格列淨]]）
			==Common Strengths of Canagliflozin Tablet==
			Canagliflozin tablets are available in the following strengths:
			*100 mg and 300 mg tablets

			==Drug Trade Names of Canagliflozin Tablet==
			Invokana

			==Drug Usage==
			*Treatment of type 2 diabetes mellitus.
			*Reducing the risk of major adverse cardiovascular events (including myocardial infarction, stroke or death) in adults with type 2 diabetes or who are at risk for cardiovascular disease.
			*Reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.

			==Mechanism of Action==
			Canagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion

			==Route of Administration==
			Oral

			==Dosages==
			*Type 2 diabetes: Starting dose 100 mg once daily, can be increased to 300 mg once daily
			*Cardiovascular risk reduction: 100 mg once daily
			*Diabetic kidney disease: 100 mg once daily
			Renal dose based on eGFR:
			*eGFR ≥60 mL/min/1.73 m<sup>2</sup>: No dose adjustment required
			*eGFR 45 to <60 mL/min/1.73 m<sup>2</sup>: 100 mg once daily
			*eGFR 30 to <45 mL/min/1.73 m<sup>2</sup>: Not recommended for glycemic control, but may be continued for cardiovascular/renal benefits
			*eGFR <30 mL/min/1.73 m<sup>2</sup>: Contraindicated

			==Side Effects==
			{\| class="wikitable"
			!style="text-align: left"\| Frequency
			!Adverse reactions
			\|-
			\| rowspan="5" \| '''Common
			\| Urinary tract infection
			\|-
			\| Male and female genital mycotic infections
			\|-
			\| Increased urination
			\|-
			\| Constipation
			\|-
			\| Joint pain
			\|-
			\| rowspan="6" \| '''Uncommon
			\| Diabetic ketoacidosis (DKA) - a condition where blood becomes too acidic
			\|-
			\| Hypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas
			\|-
			\| Hypotension
			\|-
			\| Bone fractures (associated with canagliflozin
			\|-
			\| Fournier's gangrene - a rare but serious genital infection
			\|-
			\| Lower limb amputations (associated with canagliflozin, though evidence is inconsistent)
			\|}

			==Pharmacokinetics==
			*Absorption
			**Rapidly absorbed, peak plasma concentrations within 1-2 hours
			*Metabolism
			**O-glucuronidation
			*Elimination
			**Half-life approximately 10.6 hours
			*Duration
			**24 hours (allowing for once-daily dosing)

			==Drug Precautions==
			'''Pregnancy

			Not recommended

			==Breastfeeding==

			Not recommended

			'''Children and Elderly

			Not recommended for children under 18 years. No dose adjustment is required for elderly patients

			'''Renal Impairment

			Use with caution, dosage adjustments based on eGFR

			'''Monitoring Requirements

			Renal function, volume status, signs of ketoacidosis, foot care

			'''Drug Interaction

			May increase the risk of hypoglycemia when used with insulin or insulin secretagogues

			==FAQ==
			'''How Should I Take the Tablet?

			Take once daily in the morning, with or without food

			'''What Should I Avoid While Taking?

			Avoid excessive alcohol consumption and dehydration

			'''What Happens if I Miss a Dose?

			Take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose

Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

2024-07-05T03:57:35Z

Created page with "Category: Drugs Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

New page

[[Category: Drugs]][[Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

[[:Category: Antidiabetic Drug | '''Antidiabetic Drug''']]

'''Drug class: [[:Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor | Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

'''Canagliflozin (INVOKANA)'''（中文：[[卡格列淨]]）

Canagliflozin - Revision history

Zeki: /* Breastfeeding */

Zeki at 06:20, 5 July 2024

Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."